OmniAb Inc. (OABI) - Total Liabilities
Based on the latest financial reports, OmniAb Inc. (OABI) has total liabilities worth $32.25 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore OmniAb Inc. equity growth rate to track the company's year-over-year net asset growth rate.
OmniAb Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how OmniAb Inc.'s total liabilities have evolved over time, based on quarterly financial data.
OmniAb Inc. Competitors by Total Liabilities
The table below lists competitors of OmniAb Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Healthco Healthcare and Wellness REIT
AU:HCW
|
Australia | AU$409.10 Million |
|
Petronor E&P Ltd
OL:PNOR
|
Norway | Nkr51.78 Million |
|
Huuuge Inc.
WAR:HUG
|
Poland | zł22.73 Million |
|
Saha-Union Public Company Limited
BK:SUC
|
Thailand | ฿2.41 Billion |
|
Mastersystem Infotama Tbk.
JK:MSTI
|
Indonesia | Rp1.01 Trillion |
|
Millenium Hotels Real Estate I SOCIMI S.A.
MC:YMHRE
|
Spain | €226.17 Million |
|
Fujian Sanmu Group Co Ltd
SHE:000632
|
China | CN¥7.98 Billion |
|
First Insurance Co Ltd
TW:2852
|
Taiwan | NT$9.24 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down OmniAb Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see OmniAb Inc. (OABI) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OmniAb Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OmniAb Inc. (2019–2024)
The table below shows the annual total liabilities of OmniAb Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $37.94 Million | -37.43% |
| 2023-12-31 | $60.64 Million | -24.05% |
| 2022-12-31 | $79.84 Million | +13.80% |
| 2021-12-31 | $70.16 Million | +17.24% |
| 2020-12-31 | $59.84 Million | +35.59% |
| 2019-12-31 | $44.13 Million | -- |
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partne… Read more